Linda Palczuk - Sep 1, 2023 Form 4 Insider Report for AVADEL PHARMACEUTICALS PLC (AVDL)

Role
Director
Signature
/s/ Jerad G. Seurer, as attorney-in-fact
Stock symbol
AVDL
Transactions as of
Sep 1, 2023
Transactions value $
$0
Form type
4
Date filed
9/1/2023, 09:30 PM
Previous filing
Aug 3, 2023
Next filing
Aug 1, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AVDL Stock Option (Right to Buy) Gift $0 -33K -100% $0.00* 0 Sep 1, 2023 ADSs 33K $14.10 Direct F1, F2
holding AVDL Stock Option (Right to Buy) 33K Sep 1, 2023 ADSs 33K $14.10 By Trust F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These options shall vest in full on the earlier to occur of (a) August 1, 2024 or (b) the date of the next annual general meeting of shareholders following the date of grant (August 1, 2023), subject to the Reporting Person's continued service on the Board of Directors at such time.
F2 The Issuer's "ADSs" are American Depositary Shares, with each ADS representing one ordinary share, nominal value $0.01 per share, of the issuer; ADSs may be represented by American Depositary Receipts.
F3 On September 1, 2023, the Reporting Person transferred 33,000 options to a revocable trust of which the Reporting Person is trustee.